ITGA1
- Known as:
- ITGA1
- Catalog number:
- PA1045
- Product Quantity:
- 100μg
- Category:
- -
- Supplier:
- SDlabs
- Gene target:
- ITGA1
Related genes to: ITGA1
- Gene:
- ITGA1 NIH gene
- Name:
- integrin subunit alpha 1
- Previous symbol:
- -
- Synonyms:
- VLA1, CD49a
- Chromosome:
- 5q11.2
- Locus Type:
- gene with protein product
- Date approved:
- 1992-02-27
- Date modifiied:
- 2016-10-05
Related products to: ITGA1
Related articles to: ITGA1
- Human periodontal ligament stem cells (hPDLSCs) possess promising potential for bone regeneration; however, the regulation of their osteogenic differentiation remains incompletely understood. Integrin α1 (ITGA1) has been implicated in multiple cellular processes, but its role in hPDLSC osteogenesis requires further investigation. - Source: PubMed
Publication date: 2026/07/03
Tan JieTang HaoliPeng ShuangshuangLi XinDai MengXu MaikeZhu ShijiaZhang RuiPi ChengchengJiang FuhengYang KunLi Jun - Environmental thermal-mechanical (T&M) stress threatens male fertility globally, yet no molecular therapies exist for stress-induced testicular damage. We demonstrate that macrophage-derived exosomes (Mφ-EVs) function as precision nanomedicines restoring fertility by delivering Integrin β1 (ITGB1) to repair damaged spermatogenic cytoskeletons. Using validated T&M stress models in C57BL/6 mice and GC-2 spermatocytes, we characterized severe reproductive dysfunction: 14.4% motility reduction (83.0 ± 2.0% to 71.3 ± 1.7%), 69.2% increased abnormalities (8.7 ± 2.3% to 14.7 ± 2.3%), and disrupted cytoskeletal homeostasis with Layilin (2.87-fold), Talin (3.90-fold), and Vinculin (4.24-fold) upregulation ( < 0.05). Mφ-EVs treatment achieved remarkable therapeutic efficacy: motility recovered to 80.8 ± 6.8%, abnormalities normalized to 11.6 ± 1.6% (all < 0.05). Biodistribution tracking showed that exosomes accumulate in testicular tissue (peak 8 h). Molecular docking and cellular thermal shift assays revealed exosomal ITGB1 forms high-affinity ITGA1 complexes (score -222.76), stabilizing protein structure and normalizing cytoskeletal expression. This first proof-of-concept establishes exosome-based nanotherapy as a clinically translatable, noninvasive intervention for occupational and climate-related fertility disorders, with scalable manufacturing addressing millions of men worldwide. - Source: PubMed
Publication date: 2026/06/08
Meng JiahuaWang JingyueLi ZengfengLi FeiYun XiangJin YulanZhang Lin - Natural killer (NK) cell-targeting immunotherapies are emerging, yet the differentiation and functional states of tumor-infiltrating NK cells remain poorly understood. Using matched single-nucleus RNA and ATAC sequencing of samples from patients with non-small cell lung cancer (NSCLC), we resolved the transcriptional and epigenetic landscape of intratumoral NK cells. We identified two tumor-associated NK (taNK) cell subsets marked by expression of (CD103) and (CD49a) that display features of tissue residency and dysfunction while preserving cytotoxic function. Trajectory and regulon analyses revealed an inflammation-driven transition from early () NK cells toward an (CD39) effector state characterized by interferon-stimulated gene (ISG) programs. Functional profiling established CD39 taNK cells as the dominant cytotoxic NK cell population with superior killing capacity that was further potentiated by NKG2A blockade. This study offers mechanistic insights into NK cell differentiation in NSCLC and establishes CD39 taNK cells as a targetable effector population for immunotherapy. - Source: PubMed
Publication date: 2026/06/05
Serger ClaraRebuffet LucasSandholzer Michael TRackwitz WiebkeFusi IreneHerzig PetraBrüggemann AnnaleaPawlow Carina AChichelnitskiy EvgenyHajnal DanielOelgarth NicoleUzun SarpSchultheiß ChristophZingg AndreasTundo SofiaLuu Thuy THojski AljazLardinois DidierNeubert LaviniaBinder MaschaMertz KirstenTrefny Marcel PKirchhammer NicoleNatoli MarinaMatter Matthias SLäubli HeinzFalk ChristineSchaeuble KarinVivier EricRomagnani AndreaZippelius Alfred - Blood deficiency syndrome (BDS) is a systemic disorder characterized by hematopoietic dysfunction and immune dysregulation. Given the limitations of current therapies, such as single efficacy and adverse effects, there is an urgent need for multitarget therapeutic agents with systemic regulatory effects. In this study, a mouse model of BDS was established through chronic benzene inhalation. Using an integrated transcriptomics and proteomics approach, we systematically investigated the therapeutic mechanism of Danggui Buxue Decoction (DBD). The results demonstrated that DBD significantly restored body weight, thymic and splenic indices, and bone marrow microstructure in model mice but also improved peripheral blood parameters such as the red blood cell count and mean corpuscular volume. Furthermore, DBD coordinately modulated serum hematopoietic factor and inflammatory cytokine levels. Mechanistically, DBD exerts its therapeutic effects through dual pathways. On the one hand, it promotes hematopoietic repair by upregulating transferrin receptor (TFRC) to support iron-dependent erythropoiesis, modulating KITLG/FLT3LG to maintain stem cell pool stability, and reprogramming integrin expression (e.g., upregulating ITGA4 and downregulating ITGA1) to facilitate stem cell homing and suppress fibrosis. On the other hand, it reshapes the immune microenvironment by enhancing MHC class II antigen presentation (e.g., H2Aa, H2-Ab1, H2-DMb1, and H2-Eb1) and immune cell activation (e.g., CD22, CD37, CD20, and CD8a), thereby reestablishing immune homeostasis. This study provides a systematic molecular basis for the multitarget and holistic regulatory properties of DBD, supporting its clinical application and suggesting potential therapeutic targets for BDS-related disorders. - Source: PubMed
Publication date: 2026/05/22
Liu HongdaRen JunlingHu YuYang YuSun HuiFang HengYan GuangliHan YingWang Xijun - Human tissue-resident natural killer (NK) cells (trNK cells), broadly defined by markers of tissue residency, such as CD49a [ α ()] and CD103 [ α ()], are increasingly recognized for their immunoregulatory role in host control of infection, malignancy, and autoimmunity. Although the importance of transforming growth factor-β in trNK cell differentiation has been demonstrated, the context in which the differentiation of CD49aCD103 trNK cells occurs can result in either an immunosuppressive phenotype (e.g., decidual NK cells) or a highly cytotoxic one (e.g., some tumor trNK subsets). To understand this dichotomy better, we used a multiomic approach to molecularly characterize these cells. We identified a cytotoxic trNK (ctrNK) cell population, characterized by the expression of CD39. These ctrNK cells exhibited superior cytolytic activity against tumor target cells, enhanced capacity to infiltrate into solid tumor microenvironments, and augmented ability to control solid tumor growth in vivo compared with conventionally activated peripheral NK cells. This heightened cytolytic and infiltrative functionality of ctrNK cells appeared to be conferred, in part, by the expression of CD103 and by avidity for tumor targets. Because adoptive immune cell therapy of solid tumor malignancies has been challenged by the inefficiency of ex vivo expanded immune cells to infiltrate immunosuppressive solid tumor microenvironments, our observations that ctrNK cells can be differentiated and expanded ex vivo present a potential platform for adoptive cell therapy of solid tumor malignancies. - Source: PubMed
Publication date: 2026/05/06
Horowitz Nina BMohammad Imran AShin June HoHickey John WChockley PeterSnyder GailChen ChenLee KeeneSharma KrishnaTran QuanNejatfard AnahitaMaddineni SainiteeshDivi VasuBlish Catherine ANolan Garry PFoltz Jennifer ASunwoo John B